Outside of these confirmed pathologies 5/62 (8.1%) had PVs (TP53=4, CHEK2=1), but receptor status was unknown in 43 cases, including 13 with DCIS, two of whom had a TP53 PV. This evidence concerns the gene CHEK2 and ductal breast carcinoma in situ.